Enlighten Mobility

What Enlighten Mobility does

Enlighten Mobility LLC is a private, Columbus-based neuromotor care platform founded in 2017 that operates through three interconnected portfolio areas: Early Detection, Rehabilitation, and Human Resilience. The company originated around the EDNA (Early Detection Neuromotor Assessment) technology, an AI- and computer-vision-based automated, non-invasive neuromotor screening tool for newborns that detects patterns of movement variability to enable earlier diagnosis and intervention; EDNA was developed in collaboration with Nationwide Children's Hospital and divested to AngelEye Health in 2024, which distributes it across 300+ hospitals via 10,000+ bedside cameras. In parallel, Enlighten is scaling a rehabilitation pillar via a May 2026 strategic partnership with Gravitrex Inc., contributing personnel across engineering, clinical, and commercialization functions to advance a body-weight-supported gait-training device that bridges inpatient rehabilitation and community-based care.

The firm's business model is partnership-driven and portfolio-based rather than direct-to-customer. Revenue mechanics consist of (1) technology licensing and portfolio monetization, exemplified by the EDNA divestiture, and (2) strategic advisory, consulting, and fellowship engagements delivered under the Human Resilience umbrella (patient advocacy, pediatric medical device development, innovation fellowship, market research, and brain injury care models). Distribution is indirect, routed through partners such as AngelEye Health, academic medical centers (Nationwide Children's, OSU Wexner, Michigan Medicine), and accelerator/incubator programs (Rev1 Ventures, Notre Dame ESTEEM, University of Chicago Polsky Center, AARP AgeTech Collaborative). The company operates with 1-10 employees and minimal disclosed external funding (approximately $25,000 from Elevate Ventures in 2018), consistent with a lean, founder-led operating posture that monetizes through episodic transactions and strategic collaborations rather than scaled recurring revenue.

Name

Enlighten Mobility

Legal name

Enlighten Mobility LLC

Website

https://enlightenmobility.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Enlighten Mobility is a private neuromotor care platform that develops and licenses AI-driven early-detection and rehabilitation technologies, partnering with hospitals, academic medical centers, and portfolio companies to commercialize assets such as the EDNA newborn screening system and the Gravitrex gait-training device.

Ownership category

akta.pro rank

Product category

Neuromotor Care Technology

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (621340), Services for the Elderly and Persons with Disabilities (62412)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

akta.pro secondary industries

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Balance, Fall Prevention & Gait Training In-Home (HSABADAH), Neurology Telemedicine Platforms (HLALAGAC)

Keywords

• Neuromotor care solutions
• AI movement analysis
• Rehabilitation technology
• Early detection screening
• Gait training devices

Headquarters

HQ city

South Bend

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Technology Licensing and Portfolio Monetization: Enlighten Mobility develops neuromotor technologies and commercializes them through strategic partnerships, licensing agreements, and portfolio divestitures. The sale of the EDNA portfolio to AngelEye Health demonstrates this model.
2. Strategic Advisory and Consulting: The company provides strategic advising, consulting, and fellowships to support mission-aligned initiatives that advance human resilience.

Distribution channels1 record

Marketing channels3 records

Core offering

Enlighten Mobility develops AI-powered neuromotor assessment and movement-analysis technologies for early detection and rehabilitation, and commercializes them through strategic partnerships, licensing, and portfolio sales rather than direct sales. Its portfolio includes the EDNA newborn neuromotor screening system (developed with Nationwide Children's Hospital and acquired by AngelEye Health in 2024), rehabilitation technologies such as the Gravitrex walking-assist gait training device, and Human Resilience strategic advising, consulting, and fellowship programs.

Product overview

Enlighten Mobility operates as a neuromotor care platform advancing technology, care, and innovation models through three interconnected portfolio areas: Early Detection (EDNA, now acquired by AngelEye Health), Rehabilitation (Gravitrex walking-assist device partnership), and Human Resilience (strategic advising, consulting and fellowship initiatives). The company partners with researchers, institutions, hospitals, and innovators to advance care from early detection through rehabilitation.

Differentiator

Problem solved

Functional benefit

Products and services

• EDNA (Early Detection Neuromotor Assessment) Automated, non-invasive neuromotor screening technology for newborns that uses AI and movement analysis to detect patterns of variability that can open pathways to earlier diagnosis and intervention for neuromotor conditions. Developed in collaboration with Nationwide Children's Hospital; the portfolio was acquired by AngelEye Health in 2024 and is now reaching neonatal and pediatric care teams through AngelEye's platform trusted by over 300 hospitals with over 10,000 bedside cameras deployed.
• Gravitrex Walking-Assist Device (Rehabilitation Portfolio Partnership)

Quantifiable outcome

• EDNA enables automated, non-invasive neuromotor screening for newborns
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core, moderate and minor.

• AngelEye HealthcoreStrategic or Co-development PartnerAngelEye Health acquired Enlighten Mobility's Early Detection Neuromotor Assessment (EDNA) portfolio in 2024. EDNA is an automated, non-invasive neuromotor screening for newborns developed with Nationwide Children's Hospital. AngelEye Health serves over 300 hospitals with family engagement and operational solutions. Through this strategic partnership, multiple early detection clinical studies are enrolling.
• GravitrexcoreStrategic or Co-development PartnerStrategic partnership announced in 2026 to advance the development, commercialization, and clinical adoption of next-generation rehabilitation solutions. Gravitrex is developing a walking-assist device that provides body-weight support during gait training. The partnership includes deployment of experienced personnel across engineering, clinical, and commercialization functions.
• Nationwide Children's HospitalcoreStrategic or Co-development PartnerCollaborated with Enlighten Mobility to develop the EDNA (Early Detection Neuromotor Assessment) portfolio - an automated, non-invasive neuromotor screening technology for newborns that uses AI and movement analysis.
• National Institute on AgingmoderateGTM or Marketing PartnerRecognized by the National Institute on Aging, winning its Startup Challenge. This recognition supports Gravitrex's mission to make advanced gait training available wherever recovery happens.
• University of Chicago Polsky CenterminorGTM or Marketing PartnerProvided support to Gravitrex through the University of Chicago Polsky Center startup programs.
• Arizona Commerce AuthorityminorGTM or Marketing PartnerProvided support to Gravitrex through Arizona Commerce Authority programs.
• AARP AgeTech CollaborativeminorGTM or Marketing PartnerProvided support to Gravitrex through AARP's AgeTech Collaborative initiative.
• OSU Wexner Medical CentermoderateStrategic or Co-development PartnerListed as a collaborator/institution partner in Enlighten Mobility's network advancing neuromotor care technology and innovation.
• Michigan MedicinemoderateStrategic or Co-development PartnerListed as a collaborator/institution partner in Enlighten Mobility's network advancing neuromotor care technology and innovation.
• Notre Dame ESTEEMmoderateStrategic or Co-development PartnerListed as a collaborator/institution partner in Enlighten Mobility's innovation network.
• Rev1 VenturesminorStrategic or Co-development PartnerListed as a collaborator/institution partner in Enlighten Mobility's innovation ecosystem.
• Flagship ManagementminorStrategic or Co-development PartnerListed as a collaborator/institution partner in Enlighten Mobility's innovation ecosystem.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Gravitrex: Gravitrex is developing a walking-assist device providing body-weight support during gait training, directly aligned with Enlighten Mobility's Rehabilitation portfolio focus. Enlighten Mobility has deployed personnel across engineering, clinical, and commercialization functions to support Gravitrex, making it both partner and direct operational peer in the mobility rehabilitation space.
• AlterG: AlterG manufactures anti-gravity treadmills that provide body-weight support during rehabilitation and gait training. Its technology directly addresses fall risk reduction and accessible community-based rehab, mirroring the value proposition of Enlighten Mobility's Gravitrex partnership for safer, more accessible gait training.
• ReWalk Robotics: ReWalk Robotics produces exoskeleton systems for gait rehabilitation in stroke, spinal cord injury, and multiple sclerosis patients. Its wearable robotic technology for assisted walking is directly comparable to Enlighten Mobility's Gravitrex walking-assist device thesis of bringing advanced gait training out of specialty centers.
• Ekso Bionics: Ekso Bionics develops exoskeleton and robotic rehabilitation devices for gait training and mobility recovery in clinical and personal settings. Like Enlighten Mobility's Gravitrex partnership, Ekso focuses on body-weight supported gait rehabilitation, targeting similar clinical rehabilitation use cases and customer segments.

Broad incumbents

• Sword Health: Sword Health operates a digital physical therapy and MSK care platform combining AI with human clinicians. It is comparable to Enlighten Mobility's broader thesis of using AI and movement analysis to enable earlier diagnosis and more accessible rehabilitation, though at a far larger scale and broader scope.
• Hinge Health: Hinge Health is a scaled digital musculoskeletal physical therapy platform serving employers and health plans. While broader in scope than Enlighten Mobility's pediatric/neuromotor focus, it represents the digital physical therapy category in which Enlighten Mobility's AI-driven EDNA approach could eventually compete or partner.

Others

• AngelEye Health: AngelEye Health acquired Enlighten Mobility's EDNA portfolio in 2024 and serves 300+ hospitals with neonatal/pediatric family engagement solutions. As the strategic acquirer and distribution partner for Enlighten Mobility's core early detection technology, AngelEye is the most important commercial counterpart and ecosystem participant in the company's portfolio.

Emerging players

• Cala Health: Cala Health develops wearable neuromodulation therapy devices for essential tremor and Parkinson's disease, targeting the same neuromotor condition space as Enlighten Mobility. Both companies combine AI/technology with clinical research partnerships to address unmet needs in neurologic movement disorders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enlighten Mobility